DrugPatentWatch Database Preview
FORTOVASE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Fortovase patents expire, and when can generic versions of Fortovase launch?
This drug has forty patent family members in thirty-four countries.
The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this compound. Additional details are available on the saquinavir profile page.
Summary for FORTOVASE
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 35 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,419 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | FORTOVASE at DailyMed |
Generic Entry Opportunity Date for FORTOVASE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Medical Subject Heading (MeSH) Categories for FORTOVASE
Synonyms for FORTOVASE
| (2S)-N-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide |
| (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide |
| (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide |
| (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediamide |
| (3S-(2(1R*(R*),2S*),3I,4athetav,8athetav))-N(sup 1)-(3-(3-(((1,1-Dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)butanediamide |
| (S)-N-((IS)-I-((1R)-2-((3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide |
| 127779-20-8 |
| 131176-13-1 |
| 149845-06-7 (monomethanesulfonate (salt)) |
| 1hxb |
| 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid |
| 24223-EP2269989A1 |
| 24223-EP2272516A2 |
| 24223-EP2272825A2 |
| 24223-EP2298761A1 |
| 24223-EP2298783A1 |
| 24223-EP2305640A2 |
| 24223-EP2305680A2 |
| 24223-EP2314590A1 |
| 2fgu |
| 2fgv |
| 779S208 |
| AB00514056 |
| ABP000344 |
| AC-26377 |
| AC1L9ATC |
| AKOS000280831 |
| Ambap127779-20-8 |
| AN-32602 |
| BC210734 |
| BIDD:GT0323 |
| BIDD:PXR0010 |
| BPBio1_001373 |
| BRD-K09963420-066-03-4 |
| BSPBio_001248 |
| Butanediamide, N1-((1S,2R)-3-((3S,4aS,8aS)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)- |
| Butanediamide, N1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3S-(2(1R*(R*),2S*),3alpha,4aalpha,8aalpha))- |
| Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- |
| C-23431 |
| CC-34367 |
| CHEBI:63621 |
| CHEMBL114 |
| CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE |
| CS-1180 |
| D00429 |
| D0WI3T |
| DB01232 |
| DTXSID6044012 |
| Fortovase (TN) |
| Fortovase(TM) |
| GTPL4813 |
| HMS2232L04 |
| HSDB 7161 |
| HY-17007 |
| Invirase |
| Invirase (TN) |
| Invirase(TM)(monomesylate) |
| L3JE09KZ2F |
| LS-187081 |
| MLS001195635 |
| MLS001304735 |
| MRF-0000273 |
| N-tert.butyl-decahydro -2- [2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl) -L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide |
| N-tert.butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide |
| N-tert.butyl-decahydro-2[2(R)-hydroxy-4-phenyl-3-(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide |
| N(1)-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N(2)-(quinolin-2-ylcarbonyl)-L-aspartamide |
| N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide |
| NCGC00091469-02 |
| NP-SQV |
| NSC722663 |
| PLCG-SQV |
| Prestwick0_001114 |
| Prestwick1_001114 |
| Prestwick2_001114 |
| Prestwick3_001114 |
| QNC-ASN-HPH-DIQ-NTB |
| QWAXKHKRTORLEM-UGJKXSETSA-N |
| Ro 31 8959 |
| Ro 31-8959 |
| Ro 31-8959/000 |
| Ro 318959 |
| Ro-31-8959 |
| Ro-318959000 |
| ROC |
| saguinavir |
| SAQUINAVIR |
| Saquinavir (JAN/USP/INN) |
| Saquinavir [USAN:USP:INN:BAN] |
| saquinavir methanesulfonate |
| Saquinavir-poly(lactide-co-glycolide) |
| Saquinavir/ |
| saquinavirmesylate(subjecttopatentfree) |
| SC-14020 |
| Sch 52852 |
| SCHEMBL6881 |
| sequinavir |
| SMR000469157 |
| SPBio_003114 |
| SQV |
| SQV-poly(lactide-co-glycolide) |
| UNII-L3JE09KZ2F |
| W-5153 |
| ZINC3914596 |
US Patents and Regulatory Information for FORTOVASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for FORTOVASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | ➤ Sign Up | ➤ Sign Up |
| Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for FORTOVASE
Supplementary Protection Certificates for FORTOVASE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0044 | Belgium | ➤ Sign Up | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| C0048 | Belgium | ➤ Sign Up | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| /1996 | Austria | ➤ Sign Up | PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 70013 | Netherlands | ➤ Sign Up | PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
